Boston Children’s Hospital has been granted a patent for methods and compositions to produce modified hematopoietic stem cells with increased PD-L1 expression. The invention involves modulating micro RNA expression in the cells. GlobalData’s report on Boston Children’s Hospital gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Boston Children's Hospital - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Boston Children's Hospital, was a key innovation area identified from patents. Boston Children's Hospital's grant share as of February 2024 was 56%. Grant share is based on the ratio of number of grants to total number of patents.

Modifying hematopoietic stem cells to increase pd-l1 expression

Source: United States Patent and Trademark Office (USPTO). Credit: Boston Children's Hospital

A recently granted patent (Publication Number: US11879137B2) discloses an ex vivo method for producing modified hematopoietic stem cells (HSCs) with increased expression of the programmed cell death-1 receptor ligand (PD-L1). The method involves contacting HSCs with an anti-miRNA oligonucleotide that inhibits miR-1905, leading to enhanced PD-L1 expression in the cells. The anti-miRNA oligonucleotide can be introduced to the cells using either a viral or non-viral vector.

The modified HSCs generated through this method can be obtained from various sources such as bone marrow, umbilical cord, or peripheral blood, and can be derived from healthy individuals or those with diagnosed autoimmune diseases. The modified HSCs, which can also be cryopreserved, are intended for use in treating autoimmune disorders or cancer in patients. The patent also covers compositions and populations of these modified HSCs, as well as methods for administering them to individuals in need of treatment for autoimmune disorders or cancer, including Type 1 diabetes (TID). The method outlined in the patent involves steps such as ex vivo culturing of the modified HSCs and establishing the expression of PD-L1 on the cells before administration to the patient.

To know more about GlobalData’s detailed insights on Boston Children's Hospital, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies